Mutation spectrum of the SCN1A gene in a Hungarian population with epilepsy by Till, Ágnes et al.
Contents lists available at ScienceDirect
Seizure: European Journal of Epilepsy
journal homepage: www.elsevier.com/locate/seizure
Mutation spectrum of the SCN1A gene in a Hungarian population with
epilepsy
Ágnes Tilla, Judith Zimaa, Anett Feketea,1, Judit Benea,b, Márta Czakóa,b, András Szabóa,b,
Béla Melegha,b,*, Kinga Hadzsieva,b
a Department of Medical Genetics, Medical School, Clinical Center, University of Pécs, Pécs, Hungary
b Szentágothai Research Center, University of Pécs, Pécs, Hungary







A B S T R A C T
Purpose: The vast majority of mutations responsible for epilepsy syndromes such as genetic epilepsy with febrile
seizures plus (GEFS+) and Dravet syndrome (DS) occur in the gene encoding the type 1 alpha subunit of
neuronal voltage-gated sodium channel (SCN1A).
Methods: 63 individuals presenting with either DS or GEFS + syndrome phenotype were screened for SCN1A
gene mutation using Sanger sequencing and multiplex ligation-dependent probe amplification (MLPA).
Results: Our research study identified 15 novel pathogen mutations in the SCN1A gene of which 12 appeared to
be missense mutations with addition of two frameshift-deletions and one in-frame deletion. The distribution of
clinical phenotypes in patients carrying SCN1A mutations was as follows: twelve patients had classical DS, three
patients had GEFS + syndrome and two relatives of DS patients were suffering from febrile seizures.
Conclusions: Our study highlights the phenotypic and genotypic heterogeneities of DS and GEFS + with the
important aim of gaining a deeper understanding of SCN1A-related disorders. This study also represents the first
genetic analysis of the SCN1A gene in a Hungarian cohort with the DS and GEFS + syndrome phenotype.
1. Introduction
Epilepsy, conventionally classified as idiopathic by etiology in up to
70 % of the cases, has started to reveal its genetic roots with the advent
of widely available genetic testing [1]. The majority of the genes
identified as disease causing mutation encode ion channels or receptors
including voltage-gated sodium, potassium, calcium and chloride
channels; additionally, receptors for acetylcholine and γ-amino butyric
acid (GABA) [2]. The most widely investigated association is between
SCN1A mutations (OMIM 182389) with Dravet syndrome (DS) (OMIM
607208) and the genetic epilepsy with febrile seizure plus syndrome
(GEFS+) (OMIM 604403) [3–5].
DS (previously known as severe myoclonic epilepsy in infancy,
SMEI) is one of the most common epileptic encephalopathies of infancy.
The incidence of DS is about 1 in 20,000–40,000 live births [6,7]. It is
characterized by febrile and afebrile, generalized and unilateral, clonic
or tonic-clonic seizures that are often prolonged and occur in the first
year of life in an otherwise healthy infant. The condition may be later
associated with myoclonus, atypical absences and partial seizures.
Some children, however, do not develop myoclonic symptoms and will
have a milder form of DS [8]. The seizures are frequently triggered by
fever and refractory to antiepileptic treatment. The convulsions present
commonly as febrile status epilepticus during the first year of life
[9,10]. Brain magnetic resonance imaging (MRI) shows no pathological
structural alterations in most cases and electroencephalogram (EEG)
typically remains normal at the onset of the disease [11,12]. Valproate,
stiripentol, topiramate and bromide are the mainstay of treatment
while sodium channel blocking anticonvulsants have been shown to
aggravate the seizures and therefore must be avoided [13]. Non-epi-
leptic manifestations such as intellectual disability and ataxia may ap-
pear with age.
Alterations in the gene encoding the type 1 alpha subunit of neu-
ronal voltage-gated sodium channel (SCN1A) are responsible for the
symptoms in about 70–80% of the cases [14]. The majority of changes
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are de novo mutations; however, DS shows an autosomal dominant in-
heritance pattern in 10% of the cases. In the inherited cases, relatives
carrying the same SCN1A mutation as the patient often develop milder
forms of epilepsy consistent with the phenotypic spectrum of GEFS+,
or might even stay unaffected suggesting the role of additional genes in
disease severity [15]. Familial phenotypic variability might also be
explained by mosaic SCN1A mutations in some cases [16–19]. Missense
and truncating mutations are found at approximately equal frequencies
in DS, while GEFS + is largely associated with missense mutations.
SCN1A was first described as an epilepsy-causing gene in 2001 and
more than 1200 mutations have been identified so far [20]. Despite
considerable efforts no clear phenotype-genotype correlations have
been described for the hundreds of SCN1A mutations identified [21].
The type 1 alpha subunit of the voltage-gated sodium channel is one
of the four isoforms of the mammalian voltage-gated sodium channel
alpha subunits that are expressed at high levels in the central nervous
system (CNS) [22,23]. The SCN1A gene harbours 26 exons and encodes
a 2009 amino acid-containing transmembrane protein which is a cri-
tical component of the voltage-gated sodium channels in the CNS [24].
If the alpha subunit, the core component of the transmembrane protein,
does not function normally, the sodium channel can remain closed
which, in turn, stops synaptic signal propagation to the next neuron
[25]. Murine models suggest that the primary effect of both
GEFS + and DS mutations is to decrease GABAergic inhibitory neuron
activity, contributing to seizure generation in these patients. Impaired
function of cerebellar GABAergic and inhibitory Purkinje cells may
explain the observed ataxia and cognitive impairment in these patients
[26].
The aim of this study was to investigate the mutational spectrum of
the SCN1A gene in Hungarian patients with DS and GEFS + syndrome
phenotype.
2. Materials and methods
Between January 2012 and December 2017 a total of 183
Hungarian individuals with fever-triggered and/or pharmacoresistant
epilepsy were referred for genetic examination to the Department of
Medical Genetics, University of Pécs. A total of 63 patients met the
clinical and EEG characteristics diagnostic criteria of DS as per Guerrini
and Oguni. DNA samples were examined for SCN1A gene mutations
using Sanger sequencing analysis and multiplex ligation-dependent
probe amplification (MLPA) [8]. In cases where an SCN1A mutation
was found, segregation analysis was performed to determine the mu-
tation’s de novo or inherited origin. Written informed consent was
obtained from all subjects. The collection and usage of DNA samples,
and management of data followed the Helsinki Declaration of 1975 and
also satisfying the Hungarian legal requirements of genetic examina-
tion, research and biobanking.
Genomic DNA was extracted from peripheral blood cells of the pa-
tients using the E.Z.N.A. Blood DNA Maxi Kit (Omega Bio-tek, USA)
according to the protocol of the manufacturer. As the first stage of
screening, mutation analysis was performed of the SCN1A gene (se-
quence reference: NM_001165963, NP_001159435) by direct sequen-
cing. Exons 1–26 were amplified by PCR. Primers were designed in our
laboratory (primer sequences and PCR conditions are available upon
request in our institute). Sequencing was performed with the same
primers as those applied for the PCR amplification using a BigDye
Terminator v1.1 Cycle Sequencing Kit (Applied Biosystems) according
to the manufacturer’s instructions. Interpretation of the results was
performed with the help of Mutation Taster (http://www.
mutationtaster.org), PolyPhen-2 (http://genetics.bwh.harvard.edu/
pph2) PROVEAN (http://provean.jcvi.org/index.php) and Mutation
Assessor (http://mutationassessor.org/r3) prediction software. The
identified mutations were validated on a second sample obtained from
the patients. During the second stage of screening, 33 sequence-nega-
tive patients were tested with MLPA method. MLPA was performed
with the SALSA MLPA Kit P-137 Probemix (MRC-Holland, Netherlands)
in accordance with the manufacturer’s instructions. All identified var-
iants were classified by the standards and guidelines set by the
American College of Medical Genetics and Genomics (ACMG) standards
and guidelines [27].
3. Results
A total of 12 previously described SCN1A alterations (in 15 patients
and three relatives) and 15 previously unknown pathogenic mutations
(in 15 patients and two relatives) were identified by Sanger sequencing
analysis. MLPA testing detected gross deletions of the SCN1A gene in
three additional patients. Altogether, different types of SCN1A muta-
tions were identified in 33 patients from our cohort. The inheritance
patterns could not be determined in all cases as parental samples were
not available in some families. The mutations proved to be inherited in
six cases. The parents either have developed GEFS + syndrome (Patient
1b) or suffered from febrile seizures in childhood (Patient 3c, 21b, 24b).
A couple of parents have remained unaffected (Patient 5b, 8b).
Among the previously described mutations, a recurrent, missense
mutation in exon 17 was detected (p.Thr1174Ser) in three non-con-
sanguineous patients and in the mother of one patient without any
neurological symptoms (Patients 4, 5/a, b, 20) According to the study
by Cestéle et al. (2013) the functional effects of this mutation are di-
vergent. They reported a three-generation family segregating this mu-
tation where three affected individuals had developed febrile seizures
and/or focal occipital epilepsy while two family members suffered from
typical familial hemiplegic migraine [28]. In exon 19, the recurrent
truncating mutation p.Arg1245* was identified in two non-con-
sanguineous patients presenting with classical DS phenotype (Patients
6, 7). A familial truncating mutation in exon 10 was detected in a father
and in his two daughters. While the girls were affected by classical DS,
the father merely had developed childhood febrile seizures (Patients 3/
a, b, c). A mother with GEFS+, and his son with classical DS phenotype
were harbouring a splice region variant (Patients 1/a, b). A frameshift
causing deletion and a missense mutation associated with
GEFS + phenotype (Patients 11, 13) and five other different, previously
known missense alterations associated with classical DS were also
found in our cohort (Patients 2, 8/a, 9, 10, 12). Missense and nonsense
mutations, one splice region variant and one frameshift-causing dele-
tion were detected so far (Table 1).
Three patients carried two different mutations simultaneously: two
known mutations in one case (Patient 5/a), one known and one pre-
viously undescribed variants in the other patient (Patient 20), and an-
other patient with two novel SCN1A mutations were identified (Patient
15).
Among the novel, previously undescribed SCN1A mutations 12
missense variants, two frameshift causing and one in-frame deletions
were identified (Table 2). A missense variant in the last exon of SCN1A
was detected in monozygotic twins with classic DS phenotype (Patients
26/a, b). One patient with a novel frameshift causing deletion and
another with a missense mutation had a mild type of DS as they both
appeared to have near normal cognitive ability with satisfactory sei-
zure-control at school-age (Patients 19, 20). One previously un-
described frameshift causing and one in-frame deletion in patients with
DS phenotype (Patients 16, 18) and seven other, novel missense mu-
tations associated with DS phenotype were also found in our cohort
(Patients 15, 17, 21/a, 22, 25, 27). Three novel missense mutations
associated with GEFS + phenotype were also identified (Patients 14,
23, 24/a). Two family members were detected as carriers of a pathogen
SCN1A mutation having had childhood febrile seizures only (Patients
21/b, 24/b). Using the ACMG guidelines for the interpretation of se-
quence variants, 2 of 15 novel variants were classified as “pathogenic”,
12 were classified as “likely pathogenic” and one remained a variant of
uncertain significance [27]. Significant data concerning the previously
unknown mutations and details of the important clinical features are
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listed in Tables 2 and 3.
The diagnosis of DS was confirmed with MLPA method in three
additional patients. Phenotypes of two of them were not significantly
different from those with point mutations (Patients 28, 30). On the
other hand, the third patient (Patient 29) with a large heterozygous
deletion of exon 1–17 ha d an unexpectedly mild DS phenotype. Table 4
contains relevant information about our MLPA-positive patients.
4. Discussion
SMEI or DS, as it was renamed in 1989, was first described in 1978
by Charlotte Dravet [29]. Her initial suggestion of a genetic cause was
confirmed by Claes et al. in 2001 [14]. Noting the disease’s association
with fever, Claes et al. screened for mutations in SCN1A which had been
known to cause GEFS + syndrome. Seven de novo mutations were
eventually found by the group, and SCN1A has become one of the most
relevant epilepsy genes since. Today DS is described as “a prototype of
an epileptic encephalopathy” [30,31].
Among the 63 patients with DS or GEFS + phenotype investigated
in this study pathogen alterations of the SCN1A gene have been con-
firmed in 33 patients (52,4%) and in five symptomless relatives. Twelve
previously described mutations were detected in 18 participants and 15
novel mutations were found in 17 individuals. Most of the identified
mutations proved to be missense mutations that probably alter but do
not abolish the ion channel’s function [23]. Among the discovered
mutations there were only two previously known, recurrent mutations
that were identified in more than one patient in our cohort
(p.Thr1174Ser and p.Arg1245*). In accordance with our data, previous
observations also show that out of more than 1200 reported SCN1A
mutations, only 18% are recurrent [20]. Apart from the 30 patients
with SCN1A point mutations, MLPA method revealed three cases of
SCN1A gene deletion. The frequency of MLPA-detected anomalies were
9,09% in our cohort which is similar to that published in the study of
Marini et al. (2009) [32,33]. Based on literature data, the average
Table 1
Previously described mutations in the SCN1A gene.
Patient Location Sequence change Amino acid change Mutation type Phenotype
1/a intron 5-6 c.473 + 5 het G-A – splice site DS
1/b intron 5-6 c.473 + 5 het G-A – splice site GEFS+
2 exon 9 c.1277A > G p.Tyr426Cys missense DS
3/a exon 10 c.1624 C > T p.Arg542* nonsense DS
3/b exon 10 c.1624 C > T p.Arg542* nonsense DS
3/c exon 10 c.1624 C > T p.Arg542* nonsense FS
4 exon 17 c.3521C > G p.Thr1174Ser missense GEFS+
5/a exon 17 c.3521C > G p.Thr1174Ser missense DS
5/a exon 21 c.4219C > T p.Arg1407* nonsense DS
5/b exon 17 c.3521C > G p.Thr1174Ser missense sine morbo
6 exon 19 c.3733C > T p.Arg1245* nonsense DS
7 exon 19 c.3733C > T p.Arg1245* nonsense DS
8/a exon 20 c.3924A > T p.Glu1308Asp missense DS
8/b exon 20 c.3924A > T p.Glu1308Asp missense sine morbo
9 exon 25 c.4793A > T p.Tyr1598Phe missense DS
10 exon 26 c.4934 G > A p.Arg1645Gln missense DS
11 exon 26 c.5189 T > C p.Leu1730Pro missense GEFS+
12 exon 26 c.5264A > G p.Asp1755Gly missense DS
13 exon 26 c.5536-5539delAAAC p.Lys1846SerfsX11 frameshift GEFS+
Sequence reference: NM_001165963 NP_001159435.
Patient 1/b is the mother of Patient 1/a; Patient 3/c is the father of Patient 3/a and 3/b; Patient 5/b is the mother of Patient 5/a; Patient 8/b is the mother of Patient
8/a.
Table 2
Novel mutations in the SCN1A gene.
Patient Location Sequence change Amino acid change Mutation type Phenotype ACMG-based classification and supporting evidence
14 exon 1 c.182 T > A p.Leu61His missense GEFS+ Likely pathogenic (PM2, PM6, PP2, PP3)
15 exon 2 c.364A > G p.Ile122Val missense DS Likely pathogenic (PM1, PM5, PP2, PP3)
15 exon 2 c.377 T > C p.Val126Ala missense DS Uncertain significance (PM2,PP2,PP3)
16 exon 4 c.543_545delAGA p.Glu181del in frame del DS Likely pathogenic (PM1, PM2,PM6)
17 exon 9 c.1184C > A p.Ala395Asp missense DS Likely pathogenic (PM1, PM2, PM5, PM6, PP2, PP3)
18 exon 14 c.2510delG p.Gly837ValfsX4 frameshift DS Pathogenic (PVS1, PM1, PM2, PM6, PP3)
19 exon 15 c.2666C > T p.Ala889Val missense DSb Likely pathogenic (PM1, PM2, PM6, PP2, PP3)
20a exon 18 c.3677delT p.Phe1226SerfsX2 frameshift DSb Pathogenic (PVS1, PM1, PM2, PM6, PP3)
21/a exon 21 c.4223 G > C p.Trp1408Ser missense DS Likely pathogenic (PM1, PM2, PP2, PP3)
21/b exon 21 c.4223 G > C p.Trp1408Ser missense FS Likely pathogenic (PM1, PM2, PP2, PP3)
22 exon 22 c.4322C > T p.Ala1441Val missense DS Likely pathogenic (PM2, PM6, PP2, PP3)
23 exon 22 c.4328A > C p.Asp1443Ala missense GEFS+ Likely pathogenic (PM2, PM6, PP2, PP3)
24/a exon 26 c.5332 G > C p.Val1778Leu missense GEFS+ Likely pathogenic (PM1, PM2, PP2, PP3)
24/b exon 26 c.5332 G > C p.Val1778Leu missense FS Likely pathogenic (PM1, PM2, PP2, PP3)
25 exon 26 c.5399 T > G p.Leu1800Arg missense DS Likely pathogenic (PM1, PM2, PM6, PP2, PP3)
26/a exon 26 c.5621 G > C p.Arg1874Pro missense DS Likely pathogenic (PM2, PM6, PP2, PP3)
26/b exon 26 c.5621 G > C p.Arg1874Pro missense DS Likely pathogenic (PM2, PM6, PP2, PP3)
27 exon 26 c.5438A > C p.Glu1813Ala missense DS Likely pathogenic (PM1, PM2, PM6, PP2, PP3)
Sequence reference: NM_001165963 NP_001159435.
Patient 21/b is the mother of Patient 21/a; Patient 24/b is the mother of Patient 24/a.
a This patient has an already known missense mutation (c.3521C > G, p.Thr1174Ser) also.
b Mild type of the disease with near normal cognitive ability and satisfactory seizure-control.
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frequency of MLPA-detected deletions and duplications is approxi-
mately 10–12% among SCN1A-mutation negative patients; therefore
we recommend this method as a second-tier of screening [34]. Our
patients with confirmed gross deletions of SCN1A do not show any
phenotypic difference compared to those with point mutations: febrile
and/or afebrile seizures and intellectual disability remain the char-
acteristic features in both groups. Despite the large heterozygous de-
letion, interestingly, the phenotype appeared to be a milder form of DS
in one case. In fact, evidence shows that an SCN1A deletion combined
with SCN2A and SCN3A deletions produce a more severe phenotype
than DS with earlier onset and progressive microcephaly. On the other
hand, disease associated with SCN1A and SCN9A deletions produces
milder DS phenotypes [35].
In this paper the authors aimed to further understand the genotypic
and phenotypic diversity of SCN1A gene-related disorders. Phenotype
exhibited large variability in our patient cohort, and we could not de-
tect any strong correlation between genotype and phenotype. As shown
by Fig. 1. The detected mutations cannot be localized to a hot spot
region of the gene. As Brunklaus et al. speculate, the phenotype might
not necessarily be determined only by the SCN1A protein itself, but by a
number of auxiliary proteins. [36]. Recently, Sadleir et al. identified a
recurrent SCN1A missense variant in exon 5 (c.677C > T,
p.Thr226Met) in 8 children with an early onset epileptic encephalo-
pathy much more severe than DS. The disorder is characterized by an
earlier age of onset, profound developmental impairment and a dis-
tinctive hyperkinetic movement disorder [37]. No patient with such a
mutation was detected in our cohort.
During recent years, murine Dravet models have made a significant
contribution to the better understanding of the neurobiology of the
disease [38,39]. DS as a channelopathy causes widespread Nav1.1
dysfunction throughout the brain which, in turn contributes to the
encephalopathy. This already-vulnerable system may be susceptible to
secondary aggravating events such as status epilepticus.
The early clinical diagnosis of DS may be difficult because the ty-
pical clustering of symptoms become apparent only during follow-up.
An infant with prolonged febrile seizures and a confirmed SCN1A
mutation has an SCN1A gene-related disorder. Due to the lack of con-
sistent genotype-phenotype correlations it is unpredictable whether the
disorder may lead to the evolution toward GEFS + syndrome or DS.
Recently, Cetica et al. reported that age of seizure onset in in-
dividuals with SCN1A mutations is a stronger predictor of outcome than
the type of mutation [40]. It is assumed that early recognition and
treatment to control prolonged/repeated seizures in the first year of life
might limit the progression to epileptic encephalopathy [40,41]. On the
other hand, de Lange et al. suggest that mosaicism, caused by post-
zygotic mutation, can be a major modifier of SCN1A-related diseases
[42].
One of the limitations of our study is that some mutations may pass
undetected using conventional techniques such as Sanger sequencing.
Resequencing of SCN1A – negative patients by a targeted next gen-
eration sequencing (NGS) panel comprising different epilepsy genes,
including SCN1A or by whole exome sequencing (WES) could further
refine our results [43,44]. Those patients without SCN1A mutation may
have an alternative genetic diagnosis resembling SCN1A related dis-
eases [45]. Using an NGS gene panel these patients could also obtain an
accurate diagnosis.
In the future, we are also planning to investigate genes that may
influence the severity of the GEFS + and DS phenotype. This could
further advance our understanding of the genotype-phenotype corre-
lations in patients with pathogenic SCN1A mutations.
We hope that better understanding of the pathophysiology of this
epilepsy syndrome will allow more adequate therapy and better out-
come in the future.
5. Conclusions
This work represents the first genetic analysis of the SCN1A gene in
a large Hungarian cohort with DS or GEFS + syndrome phenotype.
Fifteen novel point mutations of SCN1A gene were identified among the
12 previously described mutations. Some cases proved to be familial.
Three patients with DS phenotype harboured gross gene deletion of
SCN1A.
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Table 3
Clinical features of patients with novel mutations in the SCN1A gene.
Patient Age of onset Febrile seizure Afebrile seizure Developmental delay Intellectual disability Prolonged seizure/Status epilepticus Movement disorder
14 11 months + + – mild – –
15 4 months + + – mild + –
16 4 months + + mild NA + NA
17 5 months + + – moderate – –
18 6 months + + – NA + +
19 3 months + – – mild – –
20 3 months + + – mild – –
21/a 3 months + – – mild + –
21/b + – – – – –
22 6 months + – NA NA NA NA
23 1 year + + – – – –
24/a 1 year + + – – – –
24/b childhood + – – – – –
25 5 months + + + NA NA NA
26/a 8 months + + + NA + –
26/b 11 months + + + NA + –
27 7 months + – – NA + –
NA: data not available.
Table 4
Patients with SCN1A CNVs detected by MLPA.
Patient Genotype Phenotype
28 heterozygous whole gene deletion DS
29 heterozygous exon 1-17 deletion DS#
30 heterozygous exon 1-2 deletion DS
##Mild type of the disease with near normal cognitive ability and satisfactory
seizure-control.
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